This medicine is authorised for use in the European Union.


Kauliv is used for the treatment of osteoporosis (a disease that makes bones fragile) in the following groups:

  • women who have been through the menopause;
  • men who are at an increased risk of fractures;
  • men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid).

Kauliv is a ‘biosimilar medicine’. This means that Kauliv is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Kauliv is Forsteo. For more information on biosimilar medicines, see here.

Kauliv contains the active substance teriparatide.

This EPAR was last updated on 07/03/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Osteoporosis
  • Osteoporosis, Postmenopausal
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.


This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Publication details
Marketing-authorisation holder
Strides Pharma (Cyprus) Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Themistokli Dervi 3
1066 Nicosia

Product information

Kauliv - EMEA/H/C/004932 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Kauliv is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).

Assessment history

How useful was this page?

Add your rating